NCT06637150View on ClinicalTrials.gov

Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,388

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2030

Conditions
Breast Cancer
Interventions
DRUG

Dalpicilib

Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.

DRUG

endocrine therapy

standard endocrine therapy

Trial Locations (1)

Unknown

breast cancer institute of Fudan University Cancer Hospital, shanghai, shanghai, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT06637150 - Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer | Biotech Hunter | Biotech Hunter